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Highlights 
 
 Vincristine (VCR) induced nociception can be dose-limiting. 
 
 VCR increases permeability of the blood-spinal cord barrier. 
 
 Increased permeability results in infiltration of monocytes into the spinal cord. 
 
 Infiltrating monocytes express the pronociceptive enzyme Cathepsin S (CatS). 
 
 A centrally-penetrant CatS antagonist reduces VCR-induced nociception. 
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Abstract 
 
Chemotherapy-induced neuropathic pain is a dose-limiting side effect of many cancer 
therapies due to their propensity to accumulate in peripheral nerves, which is facilitated 
by the permeability of the blood-nerve barrier. Preclinically, the chemotherapy agent 
vincristine (VCR) activates endothelial cells in the murine peripheral nervous system 
and in doing so allows the infiltration of monocytes into nerve tissue where they 
orchestrate the development of VCR-induced nociceptive hypersensitivity. In this 
study we demonstrate that VCR also activates endothelial cells in the murine central 
nervous system, increases paracellular permeability and decreases trans endothelial 
resistance. In in vivo imaging studies in mice, VCR administration results in trafficking 
of inflammatory monocytes through the endothelium. Indeed, VCR treatment affects 
the integrity of the blood-spinal cord- barrier as indicated by Evans Blue extravasation, 
disrupts tight junction coupling and is accompanied by the presence of monocytes in 
the spinal cord. Such inflammatory monocytes (Iba-1+ CCR2+ Ly6C+ TMEM119- cells) 
that infiltrate the spinal cord also express the pro-nociceptive cysteine protease 
Cathepsin S. Systemic treatment with a CNS-penetrant, but not a peripherally-
restricted, inhibitor of Cathepsin S prevents the development of VCR-induced 
hypersensitivity, suggesting that infiltrating monocytes play a functional role in 
sensitising spinal cord nociceptive neurons. Our findings guide us towards a better 
understanding of central mechanisms of pain associated with VCR treatment and thus 
pave the way for the development of innovative antinociceptive strategies. 
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1. Introduction 
 
Neuropathic pain results from central nervous system (CNS) and peripheral nervous 
system (PNS) lesions that are accompanied by significant immune responses, such 
as those elicited by monocytes/macrophages and microglia (CNS-resident 
macrophages). These immune cells produce inflammatory mediators that contribute 
to neuropathic pain by activating nociceptive neurons (Costigan et al., 2009). The 
mechanisms that govern the involvement of immune cells however, differs between 
the CNS and PNS. 
Injury in the CNS such as that caused by traumatic spinal cord lesions can result in 
disruption of the integrity of the blood-brain barrier and the consequential infiltration of 
inflammatory monocytes, which express the chemokine receptor CCR2. Such 
infiltration, along with microglial responses, exacerbates neuronal damage and pain. 
For instance, in CNS conditions such as spinal cord injury, CCR + monocytes infiltrate 
the dorsal column and facilitate neuronal damage (Evans et al., 2014). Here they are 
recruited by the chemokine CCL2, which is expressed by perivascular macrophages 
and microglia, and contribute to inflammation (Varvel et al., 2016). 
In the instance of PNS injury however, the role of monocytes and macrophages has 
been shown to remain peripheral. Resident macrophages in the dorsal root ganglia 
(DRG) produce soluble factors, which induce the recruitment of neutrophils and 
monocytes (Santa-Cecilia et al., 2019). In addition, as a consequence of endothelial 
cell activation, monocytes are able to infiltrate into peripheral nerves following PNS 
injury, where they orchestrate the development of mechanical hypersensitivity (Old et 
al., 2014). This however, is not mirrored centrally where it is the microglial that respond 
to injury-induced increases in nociceptive neuron activity. For instance, microglia 
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release the cysteine protease Cathepsin S (CatS) that solubilises the chemokine 
domain of neuronal fractalkine (FKN), which in turn activates the CX3CR1 chemokine 
receptor in microglia (Clark et al., 2007; Clark et al., 2009). FKN activation of CX3CR1 
results in the release of pro-nociceptive cytokines, such as IL-1 (Clark et al., 
2015,Innes et al., 2019), that induce neuronal sensitisation and facilitates pain 
signalling aswell as other pathological conditions. 
Peripheral nerve injury manifests during and after treatment with a variety of 
chemotherapeutic agents, which have a broad range of actions with both shared and 
drug-specific underlying mechanisms. The blood-nerve barrier is relatively permeable 
as a result of low activity of the P-glycoprotein transporter (Balayssac et al., 2005). 
Chemotherapuetic agents consequently accumulate in peripheral nerves and cause 
neurotoxicity associated with monocyte infiltration/resident macrophage activation in 
peripheral nerves and the DRG, as well as significant nociceptive hypersensitivity (Old 
et al., 2014; Zhang et al., 2016; Shen et al., 2017; Montague et al., 2018). For example, 
in the case of hyperalgesia induced by oxaliplatin, a higher concentration of the drug is 
found in the DRG compared to the spinal cord and is critical for activation of resident 
macrophages (Shen et al., 2017). Another chemotherapeutic agent, which results in 
painful peripheral neuropathy is the vinca alkaloid vincristine (VCR). VCR treatment is 
associated with significant nociception, which is orchestrated by monocyte infiltration 
into peripheral nerves. Specifically, VCR treatment induces the expression of the 
adhesion molecules ICAM-1 and VCAM-1 in endothelial cells and consequently 
promotes the infiltration of patrolling monocytes (CX3CR high monocytes) into the sciatic 
nerve, later followed by inflammatory monocytes (CCR high/CX CR mid) as treatment 
progresses. Both patrolling and inflammatory monocytes facilitate noxious signalling 
through the release of cytokines and reactive oxygen species (ROS), which 
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sensitise sensory neurons (Old et al. 2014, Montague et al. 2018). Indeed, 
pharmacological impairment of monocyte trafficking in peripheral nerves both prevents 
and reverses VCR-induced mechanical hypersensitivity (Montague and Malcangio, 
2017). Importantly, whilst monocytes/macrophages play a mechanistic role in pain 
 
 
 
 
Old et al., 2014). 
 
 
 
 
 
 
drug distribution (Balayssac et al. 2005, Wang et al. 2010). The endothelial cells that 
form both the BBB and BSCB are tight junction-coupled. Proteins that constitute tight 
junctions include claudins, which form part of the extracellular component, and zona 
occludens proteins, which are one of the building blocks of the cytoplasmic component 
of the junction (Findley and Koval 2009). The presence of tight junctions effectively 
restricts paracellular diffusion (Abbott et al. 2010). 
In this study we explored whether VCR activates endothelial cells in the CNS and 
alters the integrity of the BSCB. We expand our knowledge regarding the role of 
monocyte signalling in VCR -induced nociception and begin to uncover a role for 
monocytes that infiltrate into the spinal cord as an indirect result of VCR treatment. 
Specifically, we uncover what we believe to be a previously unidentified alteration in 
vascular permeability of the BSCB that is mediated by VCR. We also investigate the 
effect of treatment with inhibitors of CatS on VCR-induced nociception. We use both 
associated with VCR treatment, changes in microglial number and morphology 
centrally and are not apparent when clinically-relevant doses of VCR are administered, 
as is the case with other chemotherapeutic agents (Zheng, Xiao and Bennett 2011; 
The clinical preparation of VCR - vincristine sulphate, is a large molecule (933 g/mol) 
which, despite passing through the peripheral blood-nerve barrier, does not 
accumulate centrally as it does not cross through the blood-brain barrier (BBB) or 
blood-spinal cord barrier (BSCB) where P-glycoprotein transporter efficiently limits 
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peripherally-restricted and centrally-penetrant CatS inhibitors in order to assess the 
importance of central versus peripheral monocyte-derived CatS-regulated 
mechanisms. Our findings guide us towards a better understanding of central 
mechanisms of pain associated with VCR treatment and thus pave the way for the 
development of innovative therapeutic strategies. 
2. Materials & Methods 
 
2.1 Animals 
 
Experiments were performed in accordance with the United Kingdom Animals 
(Scientific Procedures) Act 1986 and local animal care and use guidelines. All mice 
were housed under a 12 hour light/dark cycle, with food and water available ad libitum. 
For behavioural experiments both male and female cx3cr1-gfp (heterozygous and thus 
normal cx3cr1 function) were used (25-30g, 16 weeks of age). For Evans Blue 
experiments C57Bl/6 male and female mice (25-30g, 12-17 weeks of age) were used. 
For intravital experiments and immunohistochemistry CCR2-RFP (red fluorescent 
protein) mice were used for which an original breeding stock was purchased from 
Jackson Laboratory having been generated from a C57BL/6 background. CCR2 
disruption/RFP expression was confirmed by PCR using published primers (Montague 
et al., 2018). 
2.2 Behavioural testing 
 
Static mechanical withdrawal thresholds were assessed as previously described 
(Pitcher et al. 2016). Briefly, unrestrained mice were acclimatised in custom-made 
chambers for 1 hour prior to testing. Calibrated von Frey filaments (0.008-1.04g) were 
gently applied to the hind paw (plantar surface) until they started to bend and were 
held in place either for 3 seconds or until the paw was withdrawn. The 50% paw 
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withdrawal threshold (grams) was calculated using the ‘up-down’ method (starting with 
the 0.7g filament). Three baseline measurements were taken prior to experimentation, 
the mean of which is presented. Data presented are means of the left and right hind 
paw thresholds (which show no difference from each other). All behavioural tests were 
conducted by an experimenter blinded to the treatment regime. 
2.3 Drug administration 
 
Vincristine sulphate (933 g/mol, Sigma-Aldrich) was dissolved in sterile saline 0.5 
mg/kg/day and injected intraperitoneally (i.p.) using a 25-g needle either as a one-off 
injection (for 24 hours experiments) or one cycle (days 0-4 inclusive). RO5461111 
(Rupanagudi et al., 2015) and MIV-247 ((S)-N-(1-(2-amino-2-oxoacetyl)cyclobutyl)-2- 
(2,2-difluoropropanamido)-3-(1-fluorocyclopentyl) propenamide) (Hewitt et al.,  2016) 
were a gift from Medivir and were both administered orally at 200µmol/kg twice a day 
for each day of VCR treatment. MIV-247 was supplied pre-formulated in 20% 2- 
Hydroxypropyl-beta-cyclodextrin (HP-β-CD) that was used as vehicle control and 
administered at 5ml/kg (Hewitt et al., 2016). RO54461111 was dissolved in 0.5% 
methylcellulose in distilled water (that was used as vehicle control) and also 
administered at 5ml/kg. 
2.4 Immunohistochemistry 
 
Mice, under pentobarbital anaesthesia were transcardially perfused with saline and 
4% paraformaldehyde (PFA) as described previously (Montague et al. 2018). The 
lumbar enlargement was excised and post-fixed for 4 hours before being dehydrated 
in 30% sucrose and subsequently embedded in optimum cutting temperature- 
embedding medium (VWR) and snap frozen on dry ice. Fifteen μm sections were 
obtained and mounted on Superfrost Plus sides (VWR). Sections were permeabilised 
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for 15 min at room temperature in 0.1% PBS-Triton X-100 (Sigma-Aldrich) then 
blocked in 0.1% PBS-Triton X-100 + 3% BSA (Sigma-Aldrich) for 1 hour at room 
temperature before being incubated in primary antibody at 4 °C for 16 hours. Slides 
were washed three times in 0.1% PBS-Triton X-100, before being incubated with the 
appropriate fluorescently tagged secondary antibody for 1.5 hour at room temperature. 
Slides were washed three times again before being incubated for 5 min in DAPI diluted 
in PBS at 1:2000 before being washed again and then mounted using FluorSave™ 
(Merck, UK). Slides were visualised under a Zeiss LSM710 confocal microscope 
(Zeiss). Five sections per mouse were randomly selected and analysed blind as 
described previously (Old et al. 2014). 
2.5 Antibodies 
 
For monocyte/macrophages expression anti-Ly6C (1:200 Abcam) was used and 
followed by anti-rat Alexa 488 (1:1000, Invitrogen). To visualise 
microglia/macrophages, resident microglia, claudin-5 and ZO-1, anti-Iba1 (1:1000 
WAKO), anti-TMEM119 (1:500, Abcam), anti-claudin-5 (1:500, Abcam) and anti-zo-1 
(1:500, ThermoFisher scientific) were used, respectively. All were followed by anti- 
rabbit Alexa 488 (1:1000, Invitrogen). To visualise CatS, anti-CatS (1:100, Santa Cruz) 
was used followed by anti-mouse Alexa 488 (1:1000, Invitrogen). For FACS analysis 
reported below the following antibodies were used: occludin monoclonal antibody OC- 
3F10 (1:100, Invitrogen) P-glycoprotein monoclonal antibody C213 (1:10, Thermo 
Fisher Scientific). ICAM-1/VCAM-1, anti-mouse CD54 (1:200, e-BioLegend) and anti- 
mouse CD106 (1:200, e-BioLegend). Secondary coupled antibody used for occludin 
and p-Glycoprotein was an anti-mouse Alexa 488 (1:200, Life Technology). 
2.6 Western blot analysis 
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Sciatic nerves and lumbar spinal cords (dorsal) were fresh-dissected, snap-frozen and 
stored at − 80 °C until use. Tissue was homogenised in ice-cold RIPA buffer (20 mM 
tris(hydroxymethyl)aminomethane; 10 mM NaF; 150 mM NaCl; 1% nonyl- 
phenoxylpolyethoxylethanol; 1 mM phenylmethanesulfonyl fluoride; 1 mM Na3VO4 (all 
Sigma-Aldrich); and 10 mg/ml proteinase inhibitor (Roche)) before being incubated at 
4 °C with agitation for 2 hours. Samples were then centrifuged at 4 °C and 13,000 rpm 
for 20 min and the supernatant obtained was used for Western blot. Protein 
concentration was determined using the bicinchoninic acid (BCA) protein assay 
(Pierce). Twenty micrograms of protein per sample was separated on a 15% SDS- 
PAGE gel (or 8% gel for ZO-1) and transferred onto a nitrocellulose membrane in 
accordance with manufacturer’s instructions (Bio-Rad, UK). Blots were blocked for 1 
hour at room temperature in 0.1% TBS-Tween-20 (TBST) + 5% skimmed milk before 
being incubated in the required primary antibody (CatS at 1:500, Santa Cruz; Claudin- 
5 at 1:1000, Abcam; ZO-1 at 1:1000, ThermoFisher Scientific) at 4 °C overnight along 
with a loading control (β-actin (mouse or rabbit) 1:1000, Abcam). After washing in 0.1% 
TBST five times, blots were incubated for 1 hour at room temperature with the 
appropriate HRP-conjugated secondary antibody (1:2000, DAKO). Blots were washed 
before being developed with Luminata Forte Western HRP Substrate (Millipore). 
Bands were visualised using BioSpectrum© Imaging and quantified using Quantity 
One (Bio-Rad, UK). 
2.7 In vivo imaging 
 
CCR2-RFP mice were anaesthetised with an initial dose of urethane (12.5% w/v, 0.3ml 
IP). Further doses were administered approximately every 15 min to achieve surgical 
anaesthetic depth. Throughout the surgery and imaging period mice were maintained 
close to 37oC, using a homeothermic heating mat and rectal probe. For increased 
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stability and ease of breathing a tracheal catheter was installed but mice remained 
freely breathing. An incision was made in the skin above the lumbar enlargement and 
the spinal column was stabilised on a custom-made stage using spinal camps 
(Precision Systems and Instrumentation). Vertebrae over L3 and L4 spinal segment 
were removed in a laminectomy and the exposed spinal cord was cleaned and 
moistened with saline and covered with silicone elastomer (World Precision 
Instruments, Ltd). To visualise blood vessels, mice received an intravenous injection 
of 50µl dextran fluorescein (12.5 mg/ml; molecular weight: 70,000), prior to imaging. 
Mice were placed under an Eclipse Ni-E FN upright confocal/multiphoton microscope 
(Nikon) where the ambient temperature was maintained at 32oC and core body 
temperature continued near 37oC. Images were acquired using a 20x extra-long 
working distance dry objective. Dextran signal was obtained using a 488nm Argon ion 
laser whilst RFP fluorescence was obtained using 561nm diode laser. To detect the 
presence of blood vessels a single image of the Dextran and RFP signal was taken 
before and after time-lapse recording while RFP+ monocyte movement and adhesion 
was recorded for between 20 and 60 min using only RFP acquisition. 
2.8 bEND.3 cell culture 
 
The bEND3 (Immortalized Murine Brain Microvascular Endothelial Cell) cell line 
was obtained from ECACC. They originate from mouse SV129 brain endothelioma. 
The bEND3 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) 
4.5g/L D-Glucose + GlutaMAX medium (Gibco, Thermo Fisher Scientific, UK) with 
10% of foetal bovine serum (FBS-Sigma), 1:100 Non-essential Amino Acid Solution 
(NEAA) and 1:1000 Gentamicin (Gibco_Thermo Fisher Scientific-UK) 
2.9 FACS analysis 
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bEND3 cells (1X106 ) were fixed with 100μl of 2% paraformaldehyde (PFA) (Sigma- 
Aldrich, UK) for 10 min at RT. The cells were incubated in 100µl of primary antibody 
against the antigens: occludin, P-glycoprotein, ICAM and VCAM in FACS buffer 
(1% Bovine Serum Albumin in Phosphate buffered saline (PBS) with Ca2+ and Mg2+) 
in the dark for 30 min. 
When the first antibody was not coupled, cells were further incubated with a 
secondary antibody (100µl) for 30 min at RT. Sample were washed in FACS buffer, 
suspended in 200µl PBS, and analyzed at the FACS machine (BDFortessa, BD, UK) 
using a blue laser for occludin and P-glycoprotein Alexa fluor 488 (B530/30), violet 
for Pacific blues VCAM (V450/50) or Red laser for APC labelled antibody ICAM 
(R670/14). 
 
 
2.10 Paracellular Permeability 
 
 
bEND3 cells were grown on Transwell polycarbonate filters (pore size, 0.4 μm; Sigma- 
Aldrich) coated with calf skin collagen type I (Sigma-Aldrich) and paracellular 
permeability of 70-kDa FITC-dextran was assessed after stimulation as previously 
described (Dehouck et al., 1992); The permeability coefficient and clearance were 
calculated from the initial concentration of tracer in the luminal chamber and final 
concentration in the abluminal chamber: Clearance (FITC)=[C]l*Vl/[C]u where [C]u is 
the initial luminal tracer concentration, [C]l is the abluminal tracer concentration and Vl 
is the volume of the abluminal chamber. Concentration values of the lower chamber 
were calculated by plotting a standard curve of known amounts of FITC-dextran. An 
increment of cleared volumes was plotted against time of measurement (60 min). The 
total resistance coefficient opposed to the passage of the dye is the sum of the 
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resistance offered by the monolayer and the one offered by the filter itself (PStot). The 
slope of the clearance curve with a control membrane was denoted by PSmembrane. 
The real PS value for the bEND3 monolayer (PStrans) was calculated from 1/PStot. 
The PStrans values were divided by the surface area of the Transwell inserts to 
generate the permeability coefficient (Ptrans, in cm/min). Each experimental repeat 
was performed in duplicate and over at least 3-5 independent experiments. 
Transendothelial resistance (TEER) across the monolayer was determined by using 
an Endohmeter (World Precision Instruments). Resistance from coated cell-free 
inserts was always subtracted from the resistance obtained in the presence of 
endothelial cells. 
2.11 Evans Blue Injections and extraction from tissue 
 
Evans Blue powder was purchased from Sigma, UK and dissolved in sterile 0.9% 
saline at a concentration of 50 mg/ml. The solution was then filtered and administered 
intravenously into the lateral tail vein of C57Bl6 mice at 50mg/kg. Mice were placed 
back in their cages and observed regularly before tissue was fresh-dissected at 24 
hours after injection. Tissue was cut in to small pieces and weighed (approx. 300 mg) 
and incubated in 500 μl saline for 2 hours. Solutions were then centrifuged at 10,000 
rpm for 10 min. The supernatants were then treated with 1:2 trichloroacetic acid (TCA) 
before being centrifuged at 10,000 rpm for 20 min (Wang & Lai 2014). The final 
supernatant was then used to measure absorbance at 620 nm and concentration 
determined using standardized EB solutions (0.025-1000 μg/ml). EB was then 
expressed as ng/mg of tissue. 
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3. Results 
 
3.1 Vincristine upregulates adhesion molecules in CNS endothelial cells in vitro. 
 
In order to elucidate whether VCR could alter permeability of the BSCB, we began with 
an in vitro model of endothelial cells in the murine CNS, and quantified adhesion 
molecule expression as a read-out of activation. We treated bEND.3 cells with VCR 
(100nM) for 24 hours and using flow cytometry we observed that both ICAM-1 and 
VCAM-1 expression was significantly higher (p < 0.05) than under control conditions 
(Fig. 1A-D). We also observed that the expression of P-glycoprotein in VCR treated 
cells  was  significantly  higher  (p  <  0.05)  than  in  unstimulated  cells  (Fig.  1E-F). 
 
Furthermore,  VCR  treatment  significantly  decreased  (p  <  0.05)  trans-endothelial 
 
resistance and increased (p < 0.05) paracellular permeability (Fig. 1G,H) suggesting 
that VCR treatment alters endothelial functionality. 
These data indicate that VCR induces CNS endothelial cell activation, as we 
previously observed in the context of the periphery using primary HUVECs (Old et al., 
2014). In addition, the observation that VCR reduces endothelial resistance and 
increases permeability of the endothelium in vitro, suggests that VCR treatment in vivo 
could result in alteration of vascular permeability and blood cell trafficking in CNS 
tissue. 
3.2 Evidence of monocyte trafficking in the spinal cord after VCR systemic treatment. 
 
In order to assess whether VCR-induced changes in the endothelium, and thus 
potential changes in vascular permeability, were associated with blood cell trafficking 
through the endothelium, we observed monocyte trafficking in mice in which the 
chemokine receptor CCR2 is RFP-tagged and thus CCR2+ monocytes are labelled with 
RFP. CCR2 is not expressed by microglia (Mizutani et al., 2012), and therefore the 
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presence of mobile, CCR2 positive cells can be taken as evidence for monocyte 
trafficking from the blood stream to the adjacent tissue. 
CCR2-RFP mice were injected with VCR and in vivo imaging was performed in the 
spinal cord 24 hours later. We have previously observed that mechanical 
hypersensitivity occurs within 24 hours of the first dose of VCR and that in vitro, the 
endothelium is activated 24 hours after VCR treatment in vitro and so we attempted to 
investigate if monocyte infiltration into the spinal cord as a result of alterations in the 
endothelium could play a role in hypersensitivity at this timepoint. In order to visualise 
blood vessels and hence distinguish between monocytes that were present in blood 
and those that were present in tissue, we injected dextran fluorescein intravenously 
prior to imaging. We found that 24 hours after a single administration of VCR, a 
significantly higher number of RFP+ cells could be observed outside of the blood 
vessels i.e. in spinal cord tissue. Specifically, in VCR-treated mice we found 
approximately four times more RFP+ cells in spinal cord tissue compared to controls 
(p < 0.05) (Fig. 2A-C). Furthermore, we also observed preliminary evidence for 
 
significantly more (p < 0.05) adhesion of RFP+ monocytes at the vessel wall in VCR- 
treated mice (Fig. 2D). Indeed, in VCR-treated mice we observed a 2-fold increase in 
the number of monocytes located at the endothelium relative to controls suggesting a 
link between up-regulation of endothelial adhesion molecules that we observed in 
vitro, and significant increase in apparent cell adhesion. 
These data indicate that monocytes are likely to infiltrate the spinal cord after a single 
dose of VCR, suggesting that endothelial activation at the BSCB could have occurred, 
corroborating the in vitro observations obtained in endothelial cells. 
16  
3.3 Alterations in vascular permeability at the end of one cycle of VCR systemic 
treatment. 
To determine whether changes in vascular permeability in the CNS occur in vivo, and 
following a more clinically-relevant dosing regime, we treated mice with one cycle of 
VCR (5 days) and subsequently assessed Evans Blue (EB) extravasation. 
Comparable EB amounts were observed in paws prior to tissue harvesting (Fig. 3A) 
and likewise similar levels were found in liver tissue from VCR-treated and control mice 
(Fig. 3B) indicating that EB delivery and extraction were. Following VCR treatment, we 
did however measure a significant increase in the amount of detectable EB in both brain 
and spinal cord tissue, relative to controls (Fig. 3C-D). Specifically, in brain tissue from 
VCR-treated mice, the amount of EB that could be measured per mg 
of tissue was more than three times higher (p < 0.01) than that measured in brain 
tissue from control mice that had been treated with saline for 5 days (Fig. 3C). 
Likewise, when we measured EB in spinal cord tissue, levels were almost four  times 
greater (p < 0.005) in VCR-treated mice than in tissue from controls (Fig. 3D). These 
data suggest that CNS vascular permeability is selectively increased during VCR 
treatment. 
 
 
 
3.4 Disruption of tight junction protein expression and presence of infiltrating 
monocytes in the spinal cord after VCR treatment. 
We then further assessed the integrity of the BSCB after a cycle of VCR treatment by 
evaluating tight junction protein expression in order to assess whether their disruption 
could account for the increased EB permeability observed at this time point. We used 
Western blot analysis and immunohistochemistry in order to assess the expression of 
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claudin-5 and ZO-1, and their assembly on the endothelium in the murine spinal cord. 
We observed that at the end of one cycle of VCR treatment, both claudin-5 and ZO-1 
expression were significantly decreased (p < 0.01 and 0.05, respectively) relative to 
the expression levels observed in spinal cord tissue from saline-treated control mice 
(Fig. 4A-D). In addition, immunohistochemistry indicated that claudin-5 and ZO-1 
organization was fragmented and that CCR2/RFP+ profiles were clustered in regions 
where tight junction integrity was suggested to be disrupted (Fig. 4E-F). 
We then investigated whether altered vascular permeability and potential changes in 
tight junctions resulted in infiltration of monocytes into the spinal cord following one 
cycle of VCR treatment, which was suggested to occur from as soon as 24 hours after 
the first treatment as demonstrated by our intravital data. 
We detected the presence of RFP(CCR2)+/Iba1+ cells in the lumbar dorsal horn from 
VCR-treated mice (Fig. 5A) . In the spinal cord Iba1 immunoreactivity is present on 
both resident microglia and infiltrated monocytes/macrophages. However, microglia 
do not express CCR2 (Mizutani et al 2012) and thus it is possible that RFP+/Iba1+ 
cells that are observed in the spinal cord are infiltrated monocytes/ macrophages. 
Indeed, we could not detect RFP signal in cells that were positive for TMEM119, a 
specific marker for resident microglia (Fig. 5B). RFP signal however was detectable 
within TMEM119-stained sections, thus the lack of RFP signal in TMEM119 cells was 
not due to a complete lack of detectable RFP signal (Suppl. Fig. 1). Furthermore, we 
were also able to observe the presence of RFP+ cells that were also positive for the 
monocyte/macrophage precursor marker Ly6C in the dorsal horn of lumbar spinal cord 
from VCR-treated mice but not from saline-treated mice after one VCR treatment cycle 
(Fig. 5C and Suppl. Fig. 2B). Our immunohistochemical data therefore indicate that 
monocytes infiltrate into the spinal cord in the first VCR treatment cycle. 
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3.5 Functional role for infiltrating monocytes following VCR systemic treatment 
 
As we are interested in a functional role for infiltrating monocytes in the development 
of VCR-induced nociception, we postulated that these cells would provide a source of 
the pro-nociceptive enzyme CatS in the spinal cord. Indeed, monocytes/macrophages-
derived CatS exerts a pro-nociceptive action in the periphery in models of neuropathic 
pain (Barclay et al., 2007; Zhao et al., 2014). 
Following one cycle of VCR treatment we observed that the expression of CatS in the 
 
lumbar spinal cord significantly increased (p < 0.05) , as demonstrated by Western 
blot analysis (Fig. 5D). Furthermore, not only did we observe CatS immunoreactivity 
in Iba1+ cells, which is expected since CatS is normally expressed by microglia (Fig. 
5E), we also detected CatS immunoreactivity in RFP+ cells that possessed a 
morphology associated with phagocytic cells such as macrophages (Fig. 5F). 
Taken together, these data suggest that monocytes expressing CatS infiltrate into the 
spinal cord following VCR treatment and provide an additional source of the enzyme 
alongside the microglia. It is plausible that monocytes/macrophages release CatS 
instead of microglia, which are not activated following VCR treatment (Old et al., 2014). 
In order to validate the biological significance of infiltrating monocyte-derived CatS, we 
investigated whether administration of a CatS inhibitor affected the development of 
allodynia. 
3.6 A centrally-penetrant Cathepsin S inhibitor is effective in reducing VCR-induced 
nociception. 
In light of the data presented so far, we postulated that monocytes infiltrate into the 
spinal cord during VCR treatment and once there, could contribute to allodynia via the 
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release of CatS that liberates neuronal fractalkine, thus activating CX3CR1 receptors 
that are constitutively expressed by microglia (Clark et al, 2007). 
The administration of a centrally-penetrant CatS inhibitor (MIV-247) (Hewitt et al., 
 
2016) significantly (p < 0.001) reduced VCR-induced mechanical hypersensitivity 
within 24 hours of the first dose being administered and this effect persisted throughout 
the first VCR treatment cycle (Fig. 6A). However, equimolar administration of a 
peripherally-restricted CatS inhibitor (RO5461111) to VCR-treated mice during the first 
treatment cycle did not delay the onset or reduce the severity of VCR-induced 
mechanical hypersensitivity. Indeed, there was no difference in the paw withdrawal 
thresholds between VCR-treated mice who had received RO5461111 and those that 
had received the vehicle (Fig. 6B). To ensure that this lack of effect of RO5461111 
was due to the antagonist's peripheral restriction and not to an insufficient dose or 
poor oral bioavailability, we tested CatS target engagement for the antagonist in spleen 
tissue as a positive control. In the presence of a CatS inhibitor, the cleavage of Lip P10 
(P10) in B-lymphocytes and dendritic cells is blocked, resulting in accumulation of 
P10. Indeed, in spleen homogenates isolated from RO5461111- 
treated mice, we observe significant P10 accumulation (p < 0.01) suggesting that the 
antagonist is biologically active in the periphery under these experimental conditions 
(Fig. 6C, D). 
The observation that VCR-induced nociception was only significantly reduced when a 
centrally-penetrant CatS antagonist was used, does suggest that CatS plays a role 
centrally in mediating VCR mechanisms. 
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4. Discussion 
 
Chemotherapy-induced neuropathic pain is a dose-limiting side effect of many cancer 
therapies that has the capacity to diminish their success (Seretny et al 2014). It is 
therefore critical that our understanding of the underlying mechanisms of 
chemotherapy pain is advanced and thus the development of new, more effective 
therapies for pain is aided. We elucidated a previously unappreciated pathway by 
which changes in vascular permeability in the spinal cord following VCR treatment 
result in infiltration of CCR2+ monocytes that contribute to allodynia via the pro- 
nociceptive enzyme CatS (fig. 7). 
This phenomenon provides a potential means by which communication between 
peripheral immune cells and dorsal horn neurons/sensory neuron terminals in the 
spinal cord mediates nociceptive hypersensitivity during VCR treatment. 
We uncover a potential role for monocytes expressing CatS in the development of 
VCR-induced allodynia with CatS activity being more critical in the spinal cord than in 
the peripheral nerve. Specifically, we show that VCR-induced allodynia is significantly 
prevented by administration of a centrally penetrant, but not by a peripherally- 
restricted, CatS inhibitor. We have previously shown that in peripheral nerves VCR- 
induced activation of the endothelium results in infiltration of monocytes/macrophages. 
In these cells the activation of CX3CR1 receptors by FKN results in production of ROS, 
which can activate TRPA1 channels and transmit pain signalling (Old et al 2014). 
Although we know that CatS enzymatically cleaves FKN (Clark et al., 2007; 2009), 
solubilisation of endothelial FKN in peripheral nerves does not appear to contribute to 
VCR-induced allodynia. Indeed we found that a peripherally-restricted CatS antagonist 
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is devoid of anti-nociceptive effects. We discounted the possibility that this was due to 
lack of compound bioavailability and in vivo activity by confirming P10 accumulation in 
spleen. In contrast, the significant anti-nociceptive effect of a centrally-penetrant CatS 
inhibitor indicates that CatS derived from a central source plays a role in VCR-induced 
allodynia. 
In the CNS, CatS is expressed and released by microglia (Clark et al., 2007; 2010). 
 
However, changes in microglial number and morphology are not apparent in preclinical 
 
chemotherapy models (Old et al., 2014) suggesting that the microglial response is 
 
relatively mild and they are therefore unlikely to release significant amounts of CatS 
 
during VCR treatment. We suggest that monocytes/macrophages in the spinal cord 
provide a source of CatS, which we know can solubilise neuronal FKN that activates 
CX3CR1 receptor constitutively expressed by microglia. 
Specifically, we delineated a mechanistic pathway that starts with a systemic VCR- 
mediated increase in vascular permeability and endothelial activation in the spinal 
cord, which are followed by the consequential infiltration of monocytes/macrophages. 
We provide evidence for VCR’s ability to induce up-regulation of endothelial adhesion 
molecules, increase CNS vascular permeability and reduce cell resistance. We 
corroborate these in vitro data with an in vivo series of data that demonstrate increase 
of vascular permeability, monocyte trafficking and an increased in CatS expression in 
the spinal cord after VCR treatment. 
Indeed, we found evidence that permeability of the spinal cord and brain is elevated 
at the end of VCR treatment as indicated by EB extravasation. Within 24 hours of VCR 
treatment we found upregulation of adhesion molecules in endothelial cells in vitro, 
whilst in vivo we observed a significant increase in monocytes (CCR2+ cells) in 
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spinal cord tissue as well as a significant increase in cells adhering to the vessel wall, 
which is the first step of monocyte infiltration (Gerhardt and Ley 2015). Due to practical 
limitations however, the time series that we obtained were not long enough to observe 
infiltration, which would take hours longer than the maximum of 1 hour that we were 
able to obtain. 
Furthermore, we found evidence to suggest that tight junction integrity is disrupted in 
the spinal cord of VCR-treated mice. Specifically, we observed a decrease in the 
expression of the tight junction proteins claudin-5 and ZO-1 in lumbar dorsal spinal 
cord as well as a change in protein organization as suggested by our 
immunohistochemical data. Therefore, alterations in permeability of the BSCB at the 
end of one VCR treatment cycle could be a result of changes in tight junction protein 
expression. Furthermore, our observation the CCR2/RFP+ profiles accumulated in 
regions where tight junction protein organization appeared to be disrupted suggests 
that infiltration of monocytes/macrophages could be aided by the disruption of 
endothelial tight junctions in the spinal cord. 
Indeed, we observed the presence of Iba1-positive cells that were also positive for 
CCR2/RFP in the lumbar spinal cord. Both microglia and monocytes/macrophages 
express Iba1 and yet microglia do not express CCR2 (Mizutani et al 2012) and we 
observed no RFP signal in cells that were positive for the microglial marker TMEM119. 
This suggests that the origin of Iba1+/RFP+ cells in the spinal cord following VCR 
treatment is not microglia and indeed we observe cells that are positive for the 
monocyte/macrophage precursor marker; Ly6C in the spinal cord following one cycle 
of VCR treatment that are also positive for CCR2/RFP. It is also very likely that 
infiltrating monocytes/macrophages provide a source of CatS, as we also observe an 
increase in CatS protein expression after one cycle of VCR. 
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Finally, it is worth noting that endothelial cells in the CNS do not express FKN (Kim et 
al. 2011), therefore soluble FKN is unlikely to be the mechanism that accounts for 
CX3CR1-expressing monocyte trafficking in this case. 
Overall our study highlights the significance of the interaction between peripheral 
immune cells and nociceptive neurons in the spinal cord, which mediates nociceptive 
hypersensitivity during VCR treatment, a potential prototype for other chemotherapy 
drugs. Obtaining a better understanding of alterations in vascular permeability that 
occur as a result of VCR treatment begins to guide us towards a better understanding 
of potential central mechanisms that regulate pain associated this pain. 
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Figure legends 
 
Figure 1. VCR induces activation of CNS endothelial cells. Bend3 cells were 
incubated with Vincristine (100nM) or saline control for 24hours. (A) 
Representative FACS profile showing the intensity of fluorescence for ICAM 
expression. (B) Quantification of ICAM expression (n=3 independent experiments). 
28  
(C) Representative FACS profile showing the intensity of fluorescence for VCAM 
expression. (D) Quantification of VCAM (n=3 independent experiments). (E) 
Representative FACS profile showing the intensity of fluorescence for P-glycoprotein 
expression. (F) Quantification of PGP-1 expression (n=3 independent experiments). 
(G) Trans-endothelial resistance (TEER) (n=3 independent experiments). (H) 
Paracellular permeability expressed as permeability coefficient of bEND3 cells treated 
with VCR. Values are mean+/- SEM. Statistical analysis was performed by using 
Student’s t test *p<0.05 compared to saline treated cells. 
Figure 2. Increased monocyte adhesion to and infiltration into the spinal cord 24 
hours after one dose of VCR. (A-B) Representative images from a time series of 
spinal cords taken from saline (A) and VCR-treated (B) mice. Blood vessels are 
labelled with dextran fluorescein (green) and monocytes are tagged with CCR2-RFP 
(red). Scale bar = 100 μm. (C) Quantification of the number of CCR2-RFP + profiles 
observed outside of the vessel. One dose of VCR significantly increases RFP+ profiles 
found in spinal cord tissue (mean +/- SEM, n = 5 mice per group). * p < 0.05, Student’s 
paired t-test. (D) Quantification of the number of CCR2-RFP+ profiles observed at the 
endothelium. One dose of VCR significantly increases RFP+ profiles found in spinal 
cord tissue (mean +/- SEM, n = 5 mice per group). * p < 0.05, Student’s paired t-test. 
Figure 3. One cycle of VCR treatment significantly increases vascular 
permeability in brain and spinal cord. (A) Observation of paws prior to tissue 
harvesting showed no obvious difference in Evans Blue (EB) accumulation between 
saline-treated and VCR-treated mice. (B) Quantification of EB (expressed as ng/mg of 
tissue) in liver tissue from saline- and VCR-treated mice (mean+/- SEM, n = 7-8 mice 
per group). (C,D) Quantification of EB in brain (C) and spinal cord (D) from saline- 
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and VCR-treated mice (mean+/- SEM, n = 7-8 mice per group). ** p < 0.01, *** p < 
0.005, one-way ANOVA, post-hoc Tukey test. 
Figure 4. One cycle of VCR treatment disrupts expression of tight junction 
proteins in the spinal cord. (A and C) Representative blots of either Claudin-5 (A, 
24 kDa) or ZO-1 (B, 187 kDa) and -actin loading control (42 kDa) in lumbar spinal 
cord dorsal horn homogenates obtained from wild-type mice treated with one cycle of 
VCR or saline controls (days 0-4 inclusive). (B and D) Quantification of claudin-5 (B) 
and ZO-1 (D) band density normalised to loading control. VCR treatment significantly 
decreases the expression of both proteins in spinal cord homogenates. (n = 3 mice). 
* p < 0.05, ** p < 0.01, one-way ANOVA, post-hoc Tukey test. (E) Representative 
images of claudin 5 (green) and CCR2 (RFP, red) in lumbar spinal cord sections 
(dorsal horn) from saline-treated and VCR-treated mice. Nuclear stain DAPI in blue. 
(F) Representative images of ZO-1 (green) and CCR2 (RFP, red) in lumbar spinal cord 
sections (dorsal horn) from saline-treated and VCR-treated mice. Nuclear stain DAPI 
in blue Scale bars in panels in E and F = 10 μm. 
Figure 5. One cycle of VCR treatment results in monocytes/macrophages 
infiltration and CatS elevation in the spinal cord. (A) Representative images 
showing microglia/macrophage marker Iba1 (green) in saline-treated and VCR-treated 
lumbar spinal cord dorsal horn from CCR2-RFP heterozygous mice. CCR2 
immunoreactivity (RFP, red, merge yellow) is only found in Iba1+ cells in spinal cords 
from VCR-treated mice. (B) Representative image showing TMEM119 
immunoreactivity (green, resident microglia marker). No CCR2 (RFP, red) 
immunoreactivity is found in TMEM119+ cells. Nuclear marker DAPI in blue. (C) 
Representative image showing Ly6C immunoreactivity (green, monocyte/macrophage 
marker). CCR2 (RFP, red) immunoreactivity is found in Ly6C+ cells. Nuclear marker 
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DAPI in blue. (D) Representative blot and quantification of CatS (37 kDa) and -actin 
loading control (42 kDa) in lumbar spinal cord dorsal horn homogenates obtained from 
wild-type mice treated with one cycle of VCR (or saline controls). One cycle of VCR 
significantly increases CatS expression. (n = 3 mice). *p < 0.05, one-way ANOVA, 
Tukey test. (E,F) Representative image showing CatS immunoreactivity (green) in 
lumbar spinal cord dorsal horn from mice treated with one cycle of VCR. CCR2 (RFP, 
red) immunoreactivity is only found in CatS+ cells (yellow) with a phagocytic 
phenotype. Nuclear marker DAPI in blue. Scale bar in all panels = 10 μm. 
Figure 6. CatS inhibitors reduce VCR-induced mechanical hypersensitivity only 
when centrally-penetrant. (A) Mechanical thresholds are significantly higher in VCR- 
treated male and female mice (days 0-4 inclusive), which also received the centrally- 
penetrant MIV-247 (MIV) (200 µmol/kg p.o. twice a day, every day) alongside VCR 
than in VCR/vehicle-treated mice. Data expressed as 50% paw withdrawal thresholds 
(mean+/- SEM, n = 7 mice per group, 4 female and 3 male) measured 3 hours after 
administration. *** p < 0.001 compared to Saline/VEH group; ### p<0.001 compared 
to VCR/VEH group, Repeated Measures ANOVA, post hoc Tukey test. (B) Mechanical 
thresholds in mice treated with VCR (days 0-4 inclusive) are not altered 3 hours after 
administration of the peripherally-restricted RO5461111 (RO5) (200µmol/kg p.o. twice 
a day, every day) alongside VCR. Data expressed as 50% paw withdrawal thresholds 
(mean+/- SEM, n = 7 mice per group). *** p < 0.001 compared to Saline/VEH and 
Saline/RO5 groups Repeated Measures ANOVA, post hoc Tukey test. (C-D) 
Representative blot (C) and quantification (D) of li p10 fragment expression relative to 
li in snap frozen spleen from R05-treated and control mice (3 hours after 
administration) (n = 3 mice +/- SEM) ** p < 0.01, Student’s t-test. 
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Figure 7. Changes in vascular permeability following VCR treatment result in the 
infiltration of monocytes, which play a role in central mechanisms of pain. 1) 
Following treatment with vincristine (VCR), endothelial cells at the blood-spinal cord 
barrier upregulate adhesion molecules and are thus activated. 2a) VCR treatment also 
disrupts tight junction organization between endothelial cells and so monocytes, 
(which express CCR2 and are thus attracted by endothelial-expressed CCL2), are able 
to infiltrate into the spinal cord (2b). 3) Infiltrating monocytes provide a source of 
cathepsin S (CatS). 4) Cat S cleaves fractalkine (FKN) expressed by dorsal horn 
neurons. 5) Soluble FKN (sFKN) activates CX3CR1 receptors expressed by microglia, 
which in turn release proinflammatory, pronociceptive cytokines (6). 
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Abstract 
 
Chemotherapy-induced neuropathic pain is a dose-limiting side effect of many cancer 
therapies due to their propensity to accumulate in peripheral nerves, which is facilitated 
by the permeability of the blood-nerve barrier. Preclinically, the chemotherapy agent 
vincristine (VCR) activates endothelial cells in the murine peripheral nervous system 
and in doing so allows the infiltration of monocytes into nerve tissue where they 
orchestrate the development of VCR-induced nociceptive hypersensitivity. In this 
study we demonstrate that VCR also activates endothelial cells in the murine central 
nervous system, increases paracellular permeability and decreases trans endothelial 
resistance. In in vivo imaging studies in mice, VCR administration results in trafficking 
of inflammatory monocytes through the endothelium. Indeed, VCR treatment affects 
the integrity of the blood-spinal cord- barrier as indicated by Evans Blue extravasation, 
disrupts tight junction coupling and is accompanied by the presence of monocytes in 
the spinal cord. Such inflammatory monocytes (Iba-1+ CCR2+ Ly6C+ TMEM119- cells) 
that infiltrate the spinal cord also express the pro-nociceptive cysteine protease 
Cathepsin S. Systemic treatment with a CNS-penetrant, but not a peripherally-
restricted, inhibitor of Cathepsin S prevents the development of VCR-induced 
hypersensitivity, suggesting that infiltrating monocytes play a functional role in 
sensitising spinal cord nociceptive neurons. Our findings guide us towards a better 
understanding of central mechanisms of pain associated with VCR treatment and thus 
pave the way for the development of innovative antinociceptive strategies. 
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1. Introduction 
 
Neuropathic pain results from central nervous system (CNS) and peripheral nervous 
system (PNS) lesions that are accompanied by significant immune responses, such 
as those elicited by monocytes/macrophages and microglia (CNS-resident 
macrophages). These immune cells produce inflammatory mediators that contribute 
to neuropathic pain by activating nociceptive neurons (Costigan et al., 2009). The 
mechanisms that govern the involvement of immune cells however, differs between 
the CNS and PNS. 
Injury in the CNS such as that caused by traumatic spinal cord lesions can result in 
disruption of the integrity of the blood-brain barrier and the consequential infiltration of 
inflammatory monocytes, which express the chemokine receptor CCR2. Such 
infiltration, along with microglial responses, exacerbates neuronal damage and pain. 
For instance, in CNS conditions such as spinal cord injury, CCR + monocytes infiltrate 
the dorsal column and facilitate neuronal damage (Evans et al., 2014). Here they are 
recruited by the chemokine CCL2, which is expressed by perivascular macrophages 
and microglia, and contribute to inflammation (Varvel et al., 2016). 
In the instance of PNS injury however, the role of monocytes and macrophages has 
been shown to remain peripheral. Resident macrophages in the dorsal root ganglia 
(DRG) produce soluble factors, which induce the recruitment of neutrophils and 
monocytes (Santa-Cecilia et al., 2019). In addition, as a consequence of endothelial 
cell activation, monocytes are able to infiltrate into peripheral nerves following PNS 
injury, where they orchestrate the development of mechanical hypersensitivity (Old et 
al., 2014). This however, is not mirrored centrally where it is the microglial that respond 
to injury-induced increases in nociceptive neuron activity. For instance, microglia 
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release the cysteine protease Cathepsin S (CatS) that solubilises the chemokine 
domain of neuronal fractalkine (FKN), which in turn activates the CX3CR1 chemokine 
receptor in microglia (Clark et al., 2007; Clark et al., 2009). FKN activation of CX3CR1 
results in the release of pro-nociceptive cytokines, such as IL-1 (Clark et al., 2015, 
Innes et al., 2019), that induce neuronal sensitisation and facilitates pain signalling as 
well as other pathological conditions. 
Peripheral nerve injury manifests during and after treatment with a variety of 
chemotherapeutic agents, which have a broad range of actions with both shared and 
drug-specific underlying mechanisms. The blood-nerve barrier is relatively permeable 
as a result of low activity of the P-glycoprotein transporter (Balayssac et al., 2005). 
Chemotherapuetic agents consequently accumulate in peripheral nerves and cause 
neurotoxicity associated with monocyte infiltration/resident macrophage activation in 
peripheral nerves and the DRG, as well as significant nociceptive hypersensitivity (Old 
et al., 2014; Zhang et al., 2016; Shen et al., 2017; Montague et al., 2018). For example, 
in the case of hyperalgesia induced by oxaliplatin, a higher concentration of the drug 
is found in the DRG compared to the spinal cord and is critical for activation of resident 
macrophages (Shen et al., 2017). Another chemotherapeutic agent, which results in 
painful peripheral neuropathy is the vinca alkaloid vincristine (VCR). VCR treatment is 
associated with significant nociception, which is orchestrated by monocyte infiltration 
into peripheral nerves. Specifically, VCR treatment induces the expression of the 
adhesion molecules ICAM-1 and VCAM-1 in endothelial cells and consequently 
promotes the infiltration of patrolling monocytes (CX3CR high monocytes) into the sciatic 
nerve, later followed by inflammatory monocytes (CCR high/CX CR mid) as treatment 
progresses. Both patrolling and inflammatory monocytes facilitate noxious signalling 
through the release of cytokines and reactive oxygen species (ROS), which 
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sensitise sensory neurons (Old et al. 2014, Montague et al. 2018). Indeed, 
pharmacological impairment of monocyte trafficking in peripheral nerves both prevents 
and reverses VCR-induced mechanical hypersensitivity (Montague and Malcangio, 
2017). Importantly, whilst monocytes/macrophages play a mechanistic role in pain 
associated with VCR treatment, changes in microglial number and morphology 
centrally and are not apparent when clinically-relevant doses of VCR are administered, 
as is the case with other chemotherapeutic agents (Zheng, Xiao and Bennett 2011; 
Old et al., 2014). 
The clinical preparation of VCR - vincristine sulphate, is a large molecule (933 g/mol) 
which, despite passing through the peripheral blood-nerve barrier, does not 
accumulate centrally as it does not cross through the blood-brain barrier (BBB) or 
blood-spinal cord barrier (BSCB) where P-glycoprotein transporter efficiently limits 
drug distribution (Balayssac et al. 2005, Wang et al. 2010). The endothelial cells that 
form both the BBB and BSCB are tight junction-coupled. Proteins that constitute tight 
junctions include claudins, which form part of the extracellular component, and zona 
occludens proteins, which are one of the building blocks of the cytoplasmic component 
of the junction (Findley and Koval 2009). The presence of tight junctions effectively 
restricts paracellular diffusion (Abbott et al. 2010). 
In this study we explored whether VCR activates endothelial cells in the CNS and 
alters the integrity of the BSCB. We expand our knowledge regarding the role of 
monocyte signalling in VCR -induced nociception and begin to uncover a role for 
monocytes that infiltrate into the spinal cord as an indirect result of VCR treatment. 
Specifically, we uncover what we believe to be a previously unidentified alteration in 
vascular permeability of the BSCB that is mediated by VCR. We also investigate the 
effect of treatment with inhibitors of CatS on VCR-induced nociception. We use both 
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peripherally-restricted and centrally-penetrant CatS inhibitors in order to assess the 
importance of central versus peripheral monocyte-derived CatS-regulated 
mechanisms. Our findings guide us towards a better understanding of central 
mechanisms of pain associated with VCR treatment and thus pave the way for the 
development of innovative therapeutic strategies. 
2. Materials & Methods 
 
2.1 Animals 
 
Experiments were performed in accordance with the United Kingdom Animals 
(Scientific Procedures) Act 1986 and local animal care and use guidelines. All mice 
were housed under a 12 hour light/dark cycle, with food and water available ad libitum. 
For behavioural experiments both male and female cx3cr1-gfp (heterozygous and thus 
normal cx3cr1 function) were used (25-30g, 16 weeks of age). For Evans Blue 
experiments C57Bl/6 male and female mice (25-30g, 12-17 weeks of age) were used. 
For intravital experiments and immunohistochemistry CCR2-RFP (red fluorescent 
protein) mice were used for which an original breeding stock was purchased from 
Jackson Laboratory having been generated from a C57BL/6 background. CCR2 
disruption/RFP expression was confirmed by PCR using published primers (Montague 
et al., 2018). 
2.2 Behavioural testing 
 
Static mechanical withdrawal thresholds were assessed as previously described 
(Pitcher et al. 2016). Briefly, unrestrained mice were acclimatised in custom-made 
chambers for 1 hour prior to testing. Calibrated von Frey filaments (0.008-1.04g) were 
gently applied to the hind paw (plantar surface) until they started to bend and were 
held in place either for 3 seconds or until the paw was withdrawn. The 50% paw 
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withdrawal threshold (grams) was calculated using the ‘up-down’ method (starting with 
the 0.7g filament). Three baseline measurements were taken prior to experimentation, 
the mean of which is presented. Data presented are means of the left and right hind 
paw thresholds (which show no difference from each other). All behavioural tests were 
conducted by an experimenter blinded to the treatment regime. 
2.3 Drug administration 
 
Vincristine sulphate (933 g/mol, Sigma-Aldrich) was dissolved in sterile saline 0.5 
mg/kg/day and injected intraperitoneally (i.p.) using a 25-g needle either as a one-off 
injection (for 24 hours experiments) or one cycle (days 0-4 inclusive). RO5461111 
(Rupanagudi et al., 2015) and MIV-247 ((S)-N-(1-(2-amino-2-oxoacetyl)cyclobutyl)-2- 
(2,2-difluoropropanamido)-3-(1-fluorocyclopentyl) propenamide) (Hewitt et al., 2016) 
were a gift from Medivir and were both administered orally at 200µmol/kg twice a day 
for each day of VCR treatment. MIV-247 was supplied pre-formulated in 20% 2- 
Hydroxypropyl-beta-cyclodextrin (HP-β-CD) that was used as vehicle control and 
administered at 5ml/kg (Hewitt et al., 2016). RO54461111 was dissolved in 0.5% 
methylcellulose in distilled water (that was used as vehicle control) and also 
administered at 5ml/kg. 
2.4 Immunohistochemistry 
 
Mice, under pentobarbital anaesthesia were transcardially perfused with saline and 
4% paraformaldehyde (PFA) as described previously (Montague et al. 2018). The 
lumbar enlargement was excised and post-fixed for 4 hours before being dehydrated 
in 30% sucrose and subsequently embedded in optimum cutting temperature- 
embedding medium (VWR) and snap frozen on dry ice. Fifteen μm sections were 
obtained and mounted on Superfrost Plus sides (VWR). Sections were permeabilised 
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for 15 min at room temperature in 0.1% PBS-Triton X-100 (Sigma-Aldrich) then 
blocked in 0.1% PBS-Triton X-100 + 3% BSA (Sigma-Aldrich) for 1 hour at room 
temperature before being incubated in primary antibody at 4 °C for 16 hours. Slides 
were washed three times in 0.1% PBS-Triton X-100, before being incubated with the 
appropriate fluorescently tagged secondary antibody for 1.5 hour at room temperature. 
Slides were washed three times again before being incubated for 5 min in DAPI diluted 
in PBS at 1:2000 before being washed again and then mounted using FluorSave™ 
(Merck, UK). Slides were visualised under a Zeiss LSM710 confocal microscope 
(Zeiss). Five sections per mouse were randomly selected and analysed blind as 
described previously (Old et al. 2014). 
2.5 Antibodies 
 
For monocyte/macrophages expression anti-Ly6C (1:200 Abcam) was used and 
followed by anti-rat Alexa 488 (1:1000, Invitrogen). To visualise 
microglia/macrophages, resident microglia, claudin-5 and ZO-1, anti-Iba1 (1:1000 
WAKO), anti-TMEM119 (1:500, Abcam), anti-claudin-5 (1:500, Abcam) and anti-zo-1 
(1:500, ThermoFisher scientific) were used, respectively. All were followed by anti- 
rabbit Alexa 488 (1:1000, Invitrogen). To visualise CatS, anti-CatS (1:100, Santa Cruz) 
was used followed by anti-mouse Alexa 488 (1:1000, Invitrogen). For FACS analysis 
reported below the following antibodies were used: occludin monoclonal antibody OC- 
3F10 (1:100, Invitrogen) P-glycoprotein monoclonal antibody C213 (1:10, Thermo 
Fisher Scientific). ICAM-1/VCAM-1, anti-mouse CD54 (1:200, e-BioLegend) and anti- 
mouse CD106 (1:200, e-BioLegend). Secondary coupled antibody used for occludin 
and p-Glycoprotein was an anti-mouse Alexa 488 (1:200, Life Technology). 
2.6 Western blot analysis 
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Sciatic nerves and lumbar spinal cords (dorsal) were fresh-dissected, snap-frozen and 
stored at − 80 °C until use. Tissue was homogenised in ice-cold RIPA buffer (20 mM 
tris(hydroxymethyl)aminomethane; 10 mM NaF; 150 mM NaCl; 1% nonyl- 
phenoxylpolyethoxylethanol; 1 mM phenylmethanesulfonyl fluoride; 1 mM Na3VO4 (all 
Sigma-Aldrich); and 10 mg/ml proteinase inhibitor (Roche)) before being incubated at 
4 °C with agitation for 2 hours. Samples were then centrifuged at 4 °C and 13,000 rpm 
for 20 min and the supernatant obtained was used for Western blot. Protein 
concentration was determined using the bicinchoninic acid (BCA) protein assay 
(Pierce). Twenty micrograms of protein per sample was separated on a 15% SDS- 
PAGE gel (or 8% gel for ZO-1) and transferred onto a nitrocellulose membrane in 
accordance with manufacturer’s instructions (Bio-Rad, UK). Blots were blocked for 1 
hour at room temperature in 0.1% TBS-Tween-20 (TBST) + 5% skimmed milk before 
being incubated in the required primary antibody (CatS at 1:500, Santa Cruz; Claudin- 
5 at 1:1000, Abcam; ZO-1 at 1:1000, ThermoFisher Scientific) at 4 °C overnight along 
with a loading control (β-actin (mouse or rabbit) 1:1000, Abcam). After washing in 0.1% 
TBST five times, blots were incubated for 1 hour at room temperature with the 
appropriate HRP-conjugated secondary antibody (1:2000, DAKO). Blots were washed 
before being developed with Luminata Forte Western HRP Substrate (Millipore). 
Bands were visualised using BioSpectrum© Imaging and quantified using Quantity 
One (Bio-Rad, UK). 
2.7 In vivo imaging 
 
CCR2-RFP mice were anaesthetised with an initial dose of urethane (12.5% w/v, 0.3ml 
IP). Further doses were administered approximately every 15 min to achieve surgical 
anaesthetic depth. Throughout the surgery and imaging period mice were maintained 
close to 37oC, using a homeothermic heating mat and rectal probe. For increased 
11  
stability and ease of breathing a tracheal catheter was installed but mice remained 
freely breathing. An incision was made in the skin above the lumbar enlargement and 
the spinal column was stabilised on a custom-made stage using spinal camps 
(Precision Systems and Instrumentation). Vertebrae over L3 and L4 spinal segment 
were removed in a laminectomy and the exposed spinal cord was cleaned and 
moistened with saline and covered with silicone elastomer (World Precision 
Instruments, Ltd). To visualise blood vessels, mice received an intravenous injection 
of 50µl dextran fluorescein (12.5 mg/ml; molecular weight: 70,000), prior to imaging. 
Mice were placed under an Eclipse Ni-E FN upright confocal/multiphoton microscope 
(Nikon) where the ambient temperature was maintained at 32oC and core body 
temperature continued near 37oC. Images were acquired using a 20x extra-long 
working distance dry objective. Dextran signal was obtained using a 488nm Argon ion 
laser whilst RFP fluorescence was obtained using 561nm diode laser. To detect the 
presence of blood vessels a single image of the Dextran and RFP signal was taken 
before and after time-lapse recording while RFP+ monocyte movement and adhesion 
was recorded for between 20 and 60 min using only RFP acquisition. 
2.8 bEND.3 cell culture 
 
The bEND3 (Immortalized Murine Brain Microvascular Endothelial Cell) cell line 
was obtained from ECACC. They originate from mouse SV129 brain endothelioma. 
The bEND3 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) 
4.5g/L D-Glucose + GlutaMAX medium (Gibco, Thermo Fisher Scientific, UK) with 
10% of foetal bovine serum (FBS-Sigma), 1:100 Non-essential Amino Acid Solution 
(NEAA) and 1:1000 Gentamicin (Gibco_Thermo Fisher Scientific-UK) 
2.9 FACS analysis 
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bEND3 cells (1X106 ) were fixed with 100μl of 2% paraformaldehyde (PFA) (Sigma- 
Aldrich, UK) for 10 min at RT. The cells were incubated in 100µl of primary antibody 
against the antigens: occludin, P-glycoprotein, ICAM and VCAM in FACS buffer 
(1% Bovine Serum Albumin in Phosphate buffered saline (PBS) with Ca2+ and Mg2+) 
in the dark for 30 min. 
When the first antibody was not coupled, cells were further incubated with a 
secondary antibody (100µl) for 30 min at RT. Sample were washed in FACS buffer, 
suspended in 200µl PBS, and analyzed at the FACS machine (BDFortessa, BD, UK) 
using a blue laser for occludin and P-glycoprotein Alexa fluor 488 (B530/30), violet 
for Pacific blues VCAM (V450/50) or Red laser for APC labelled antibody ICAM 
(R670/14). 
 
 
2.10 Paracellular Permeability 
 
 
bEND3 cells were grown on Transwell polycarbonate filters (pore size, 0.4 μm; Sigma- 
Aldrich) coated with calf skin collagen type I (Sigma-Aldrich) and paracellular 
permeability of 70-kDa FITC-dextran was assessed after stimulation as previously 
described (Dehouck et al., 1992); The permeability coefficient and clearance were 
calculated from the initial concentration of tracer in the luminal chamber and final 
concentration in the abluminal chamber: Clearance (FITC)=[C]l*Vl/[C]u where [C]u is 
the initial luminal tracer concentration, [C]l is the abluminal tracer concentration and Vl 
is the volume of the abluminal chamber. Concentration values of the lower chamber 
were calculated by plotting a standard curve of known amounts of FITC-dextran. An 
increment of cleared volumes was plotted against time of measurement (60 min). The 
total resistance coefficient opposed to the passage of the dye is the sum of the 
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resistance offered by the monolayer and the one offered by the filter itself (PStot). The 
slope of the clearance curve with a control membrane was denoted by PSmembrane. 
The real PS value for the bEND3 monolayer (PStrans) was calculated from 1/PStot. 
The PStrans values were divided by the surface area of the Transwell inserts to 
generate the permeability coefficient (Ptrans, in cm/min). Each experimental repeat 
was performed in duplicate and over at least 3-5 independent experiments. 
Transendothelial resistance (TEER) across the monolayer was determined by using 
an Endohmeter (World Precision Instruments). Resistance from coated cell-free 
inserts was always subtracted from the resistance obtained in the presence of 
endothelial cells. 
2.11 Evans Blue Injections and extraction from tissue 
 
Evans Blue powder was purchased from Sigma, UK and dissolved in sterile 0.9% 
saline at a concentration of 50 mg/ml. The solution was then filtered and administered 
intravenously into the lateral tail vein of C57Bl6 mice at 50mg/kg. Mice were placed 
back in their cages and observed regularly before tissue was fresh-dissected at 24 
hours after injection. Tissue was cut in to small pieces and weighed (approx. 300 mg) 
and incubated in 500 μl saline for 2 hours. Solutions were then centrifuged at 10,000 
rpm for 10 min. The supernatants were then treated with 1:2 trichloroacetic acid (TCA) 
before being centrifuged at 10,000 rpm for 20 min (Wang & Lai 2014). The final 
supernatant was then used to measure absorbance at 620 nm and concentration 
determined using standardized EB solutions (0.025-1000 μg/ml). EB was then 
expressed as ng/mg of tissue. 
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3. Results 
 
3.1 Vincristine upregulates adhesion molecules in CNS endothelial cells in vitro. 
 
In order to elucidate whether VCR could alter permeability of the BSCB, we began with 
an in vitro model of endothelial cells in the murine CNS, and quantified adhesion 
molecule expression as a read-out of activation. We treated bEND.3 cells with VCR 
(100nM) for 24 hours and using flow cytometry we observed that both ICAM-1 and 
VCAM-1 expression was significantly higher (p < 0.05) than under control conditions 
(Fig. 1A-D). We also observed that the expression of P-glycoprotein in VCR treated 
cells was significantly higher (p < 0.05) than in unstimulated cells (Fig. 1E-F). 
Furthermore, VCR treatment significantly decreased (p < 0.05) trans-endothelial 
resistance and increased (p < 0.05) paracellular permeability (Fig. 1G,H) suggesting 
that VCR treatment alters endothelial functionality. 
These data indicate that VCR induces CNS endothelial cell activation, as we 
previously observed in the context of the periphery using primary HUVECs (Old et al., 
2014). In addition, the observation that VCR reduces endothelial resistance and 
increases permeability of the endothelium in vitro, suggests that VCR treatment in vivo 
could result in alteration of vascular permeability and blood cell trafficking in CNS 
tissue. 
3.2 Evidence of monocyte trafficking in the spinal cord after VCR systemic treatment. 
 
In order to assess whether VCR-induced changes in the endothelium, and thus 
potential changes in vascular permeability, were associated with blood cell trafficking 
through the endothelium, we observed monocyte trafficking in mice in which the 
chemokine receptor CCR2 is RFP-tagged and thus CCR2+ monocytes are labelled with 
RFP. CCR2 is not expressed by microglia (Mizutani et al., 2012), and therefore the 
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presence of mobile, CCR2 positive cells can be taken as evidence for monocyte 
trafficking from the blood stream to the adjacent tissue. 
CCR2-RFP mice were injected with VCR and in vivo imaging was performed in the 
spinal cord 24 hours later. We have previously observed that mechanical 
hypersensitivity occurs within 24 hours of the first dose of VCR and that in vitro, the 
endothelium is activated 24 hours after VCR treatment in vitro and so we attempted to 
investigate if monocyte infiltration into the spinal cord as a result of alterations in the 
endothelium could play a role in hypersensitivity at this timepoint. In order to visualise 
blood vessels and hence distinguish between monocytes that were present in blood 
and those that were present in tissue, we injected dextran fluorescein intravenously 
prior to imaging. We found that 24 hours after a single administration of VCR, a 
significantly higher number of RFP+ cells could be observed outside of the blood 
vessels i.e. in spinal cord tissue. Specifically, in VCR-treated mice we found 
approximately four times more RFP+ cells in spinal cord tissue compared to controls 
(p < 0.05) (Fig. 2A-C). Furthermore, we also observed preliminary evidence for 
significantly more (p < 0.05) adhesion of RFP+ monocytes at the vessel wall in VCR- 
treated mice (Fig. 2D). Indeed, in VCR-treated mice we observed a 2-fold increase in 
the number of monocytes located at the endothelium relative to controls suggesting a 
link between up-regulation of endothelial adhesion molecules that we observed in 
vitro, and significant increase in apparent cell adhesion. 
These data indicate that monocytes are likely to infiltrate the spinal cord after a single 
dose of VCR, suggesting that endothelial activation at the BSCB could have occurred, 
corroborating the in vitro observations obtained in endothelial cells. 
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3.3 Alterations in vascular permeability at the end of one cycle of VCR systemic 
treatment. 
To determine whether changes in vascular permeability in the CNS occur in vivo, and 
following a more clinically-relevant dosing regime, we treated mice with one cycle of 
VCR (5 days) and subsequently assessed Evans Blue (EB) extravasation. 
Comparable EB amounts were observed in paws prior to tissue harvesting (Fig. 3A) 
and likewise similar levels were found in liver tissue from VCR-treated and control mice 
(Fig. 3B) indicating that EB delivery and extraction were. Following VCR treatment, we 
did however measure a significant increase in the amount of detectable EB in both brain 
and spinal cord tissue, relative to controls (Fig. 3C-D). Specifically, in brain tissue from 
VCR-treated mice, the amount of EB that could be measured per mg of tissue was 
more than three times higher (p < 0.01) than that measured in brain tissue from control 
mice that had been treated with saline for 5 days (Fig. 3C). Likewise, when we 
measured EB in spinal cord tissue, levels were almost four times greater (p < 0.005) 
in VCR-treated mice than in tissue from controls (Fig. 3D). These data suggest that 
CNS vascular permeability is selectively increased during VCR treatment. 
 
 
 
3.4 Disruption of tight junction protein expression and presence of infiltrating 
monocytes in the spinal cord after VCR treatment. 
We then further assessed the integrity of the BSCB after a cycle of VCR treatment by 
evaluating tight junction protein expression in order to assess whether their disruption 
could account for the increased EB permeability observed at this time point. We used 
Western blot analysis and immunohistochemistry in order to assess the expression of 
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claudin-5 and ZO-1, and their assembly on the endothelium in the murine spinal cord. 
We observed that at the end of one cycle of VCR treatment, both claudin-5 and ZO-1 
expression were significantly decreased (p < 0.01 and 0.05, respectively) relative to 
the expression levels observed in spinal cord tissue from saline-treated control mice 
(Fig. 4A-D). In addition, immunohistochemistry indicated that claudin-5 and ZO-1 
organization was fragmented and that CCR2/RFP+ profiles were clustered in regions 
where tight junction integrity was suggested to be disrupted (Fig. 4E-F). 
We then investigated whether altered vascular permeability and potential changes in 
tight junctions resulted in infiltration of monocytes into the spinal cord following one 
cycle of VCR treatment, which was suggested to occur from as soon as 24 hours after 
the first treatment as demonstrated by our intravital data. 
We detected the presence of RFP(CCR2)+/Iba1+ cells in the lumbar dorsal horn from 
VCR-treated mice (Fig. 5A) . In the spinal cord Iba1 immunoreactivity is present on 
both resident microglia and infiltrated monocytes/macrophages. However, microglia 
do not express CCR2 (Mizutani et al 2012) and thus it is possible that RFP+/Iba1+ 
cells that are observed in the spinal cord are infiltrated monocytes/ macrophages. 
Indeed, we could not detect RFP signal in cells that were positive for TMEM119, a 
specific marker for resident microglia (Fig. 5B). RFP signal however was detectable 
within TMEM119-stained sections, thus the lack of RFP signal in TMEM119 cells was 
not due to a complete lack of detectable RFP signal (Suppl. Fig. 1). Furthermore, we 
were also able to observe the presence of RFP+ cells that were also positive for the 
monocyte/macrophage precursor marker Ly6C in the dorsal horn of lumbar spinal cord 
from VCR-treated mice but not from saline-treated mice after one VCR treatment cycle 
(Fig. 5C and Suppl. Fig. 2B). Our immunohistochemical data therefore indicate that 
monocytes infiltrate into the spinal cord in the first VCR treatment cycle. 
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3.5 Functional role for infiltrating monocytes following VCR systemic treatment 
 
As we are interested in a functional role for infiltrating monocytes in the development 
of VCR-induced nociception, we postulated that these cells would provide a source of 
the pro-nociceptive enzyme CatS in the spinal cord. Indeed, monocytes/macrophages-
derived CatS exerts a pro-nociceptive action in the periphery in models of neuropathic 
pain (Barclay et al., 2007; Zhao et al., 2014). 
Following one cycle of VCR treatment we observed that the expression of CatS in the 
lumbar spinal cord significantly increased (p < 0.05) , as demonstrated by Western 
blot analysis (Fig. 5D). Furthermore, not only did we observe CatS immunoreactivity 
in Iba1+ cells, which is expected since CatS is normally expressed by microglia (Fig. 
5E), we also detected CatS immunoreactivity in RFP+ cells that possessed a 
morphology associated with phagocytic cells such as macrophages (Fig. 5F). 
Taken together, these data suggest that monocytes expressing CatS infiltrate into the 
spinal cord following VCR treatment and provide an additional source of the enzyme 
alongside the microglia. It is plausible that monocytes/macrophages release CatS 
instead of microglia, which are not activated following VCR treatment (Old et al., 2014). 
In order to validate the biological significance of infiltrating monocyte-derived CatS, we 
investigated whether administration of a CatS inhibitor affected the development of 
allodynia. 
3.6 A centrally-penetrant Cathepsin S inhibitor is effective in reducing VCR-induced 
nociception. 
In light of the data presented so far, we postulated that monocytes infiltrate into the 
spinal cord during VCR treatment and once there, could contribute to allodynia via the 
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release of CatS that liberates neuronal fractalkine, thus activating CX3CR1 receptors 
that are constitutively expressed by microglia (Clark et al, 2007). 
The administration of a centrally-penetrant CatS inhibitor (MIV-247) (Hewitt et al., 
2016) significantly (p < 0.001) reduced VCR-induced mechanical hypersensitivity 
within 24 hours of the first dose being administered and this effect persisted throughout 
the first VCR treatment cycle (Fig. 6A). However, equimolar administration of a 
peripherally-restricted CatS inhibitor (RO5461111) to VCR-treated mice during the first 
treatment cycle did not delay the onset or reduce the severity of VCR-induced 
mechanical hypersensitivity. Indeed, there was no difference in the paw withdrawal 
thresholds between VCR-treated mice who had received RO5461111 and those that 
had received the vehicle (Fig. 6B). To ensure that this lack of effect of RO5461111 
was due to the antagonist's peripheral restriction and not to an insufficient dose or 
poor oral bioavailability, we tested CatS target engagement for the antagonist in spleen 
tissue as a positive control. In the presence of a CatS inhibitor, the cleavage of Lip P10 
(P10) in B-lymphocytes and dendritic cells is blocked, resulting in accumulation of P10. 
Indeed, in spleen homogenates isolated from RO5461111- treated mice, we observe 
significant P10 accumulation (p < 0.01) suggesting that the antagonist is biologically 
active in the periphery under these experimental conditions (Fig. 6C, D). 
The observation that VCR-induced nociception was only significantly reduced when a 
centrally-penetrant CatS antagonist was used, does suggest that CatS plays a role 
centrally in mediating VCR mechanisms. 
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4. Discussion 
 
Chemotherapy-induced neuropathic pain is a dose-limiting side effect of many cancer 
therapies that has the capacity to diminish their success (Seretny et al 2014). It is 
therefore critical that our understanding of the underlying mechanisms of 
chemotherapy pain is advanced and thus the development of new, more effective 
therapies for pain is aided. We elucidated a previously unappreciated pathway by 
which changes in vascular permeability in the spinal cord following VCR treatment 
result in infiltration of CCR2+ monocytes that contribute to allodynia via the pro- 
nociceptive enzyme CatS (fig. 7). 
This phenomenon provides a potential means by which communication between 
peripheral immune cells and dorsal horn neurons/sensory neuron terminals in the 
spinal cord mediates nociceptive hypersensitivity during VCR treatment. 
We uncover a potential role for monocytes expressing CatS in the development of 
VCR-induced allodynia with CatS activity being more critical in the spinal cord than in 
the peripheral nerve. Specifically, we show that VCR-induced allodynia is significantly 
prevented by administration of a centrally penetrant, but not by a peripherally- 
restricted, CatS inhibitor. We have previously shown that in peripheral nerves VCR- 
induced activation of the endothelium results in infiltration of monocytes/macrophages. 
In these cells the activation of CX3CR1 receptors by FKN results in production of ROS, 
which can activate TRPA1 channels and transmit pain signalling (Old et al 2014). 
Although we know that CatS enzymatically cleaves FKN (Clark et al., 2007; 2009), 
solubilisation of endothelial FKN in peripheral nerves does not appear to contribute to 
VCR-induced allodynia. Indeed we found that a peripherally-restricted CatS antagonist 
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is devoid of anti-nociceptive effects. We discounted the possibility that this was due to 
lack of compound bioavailability and in vivo activity by confirming P10 accumulation in 
spleen. In contrast, the significant anti-nociceptive effect of a centrally-penetrant CatS 
inhibitor indicates that CatS derived from a central source plays a role in VCR-induced 
allodynia. 
In the CNS, CatS is expressed and released by microglia (Clark et al., 2007; 2010). 
However, changes in microglial number and morphology are not apparent in preclinical 
chemotherapy models (Old et al., 2014) suggesting that the microglial response is 
relatively mild and they are therefore unlikely to release significant amounts of CatS 
during VCR treatment. We suggest that monocytes/macrophages in the spinal cord 
provide a source of CatS, which we know can solubilise neuronal FKN that activates 
CX3CR1 receptor constitutively expressed by microglia. 
Specifically, we delineated a mechanistic pathway that starts with a systemic VCR- 
mediated increase in vascular permeability and endothelial activation in the spinal 
cord, which are followed by the consequential infiltration of monocytes/macrophages. 
We provide evidence for VCR’s ability to induce up-regulation of endothelial adhesion 
molecules, increase CNS vascular permeability and reduce cell resistance. We 
corroborate these in vitro data with an in vivo series of data that demonstrate increase 
of vascular permeability, monocyte trafficking and an increased in CatS expression in 
the spinal cord after VCR treatment. 
Indeed, we found evidence that permeability of the spinal cord and brain is elevated 
at the end of VCR treatment as indicated by EB extravasation. Within 24 hours of VCR 
treatment we found upregulation of adhesion molecules in endothelial cells in vitro, 
whilst in vivo we observed a significant increase in monocytes (CCR2+ cells) in 
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spinal cord tissue as well as a significant increase in cells adhering to the vessel wall, 
which is the first step of monocyte infiltration (Gerhardt and Ley 2015). Due to practical 
limitations however, the time series that we obtained were not long enough to observe 
infiltration, which would take hours longer than the maximum of 1 hour that we were 
able to obtain. 
Furthermore, we found evidence to suggest that tight junction integrity is disrupted in 
the spinal cord of VCR-treated mice. Specifically, we observed a decrease in the 
expression of the tight junction proteins claudin-5 and ZO-1 in lumbar dorsal spinal 
cord as well as a change in protein organization as suggested by our 
immunohistochemical data. Therefore, alterations in permeability of the BSCB at the 
end of one VCR treatment cycle could be a result of changes in tight junction protein 
expression. Furthermore, our observation the CCR2/RFP+ profiles accumulated in 
regions where tight junction protein organization appeared to be disrupted suggests 
that infiltration of monocytes/macrophages could be aided by the disruption of 
endothelial tight junctions in the spinal cord. 
Indeed, we observed the presence of Iba1-positive cells that were also positive for 
CCR2/RFP in the lumbar spinal cord. Both microglia and monocytes/macrophages 
express Iba1 and yet microglia do not express CCR2 (Mizutani et al 2012) and we 
observed no RFP signal in cells that were positive for the microglial marker TMEM119. 
This suggests that the origin of Iba1+/RFP+ cells in the spinal cord following VCR 
treatment is not microglia and indeed we observe cells that are positive for the 
monocyte/macrophage precursor marker; Ly6C in the spinal cord following one cycle 
of VCR treatment that are also positive for CCR2/RFP. It is also very likely that 
infiltrating monocytes/macrophages provide a source of CatS, as we also observe an 
increase in CatS protein expression after one cycle of VCR. 
23  
Finally, it is worth noting that endothelial cells in the CNS do not express FKN (Kim et 
al. 2011), therefore soluble FKN is unlikely to be the mechanism that accounts for 
CX3CR1-expressing monocyte trafficking in this case. 
Overall our study highlights the significance of the interaction between peripheral 
immune cells and nociceptive neurons in the spinal cord, which mediates nociceptive 
hypersensitivity during VCR treatment, a potential prototype for other chemotherapy 
drugs. Obtaining a better understanding of alterations in vascular permeability that 
occur as a result of VCR treatment begins to guide us towards a better understanding 
of potential central mechanisms that regulate pain associated this pain. 
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Figure legends 
 
Figure 1. VCR induces activation of CNS endothelial cells. Bend3 cells were 
incubated with Vincristine (100nM) or saline control for 24hours. (A) 
Representative FACS profile showing the intensity of fluorescence for ICAM 
expression. (B) Quantification of ICAM expression (n=3 independent experiments). 
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(C) Representative FACS profile showing the intensity of fluorescence for VCAM 
expression. (D) Quantification of VCAM (n=3 independent experiments). (E) 
Representative FACS profile showing the intensity of fluorescence for P-glycoprotein 
expression. (F) Quantification of PGP-1 expression (n=3 independent experiments). 
(G) Trans-endothelial resistance (TEER) (n=3 independent experiments). (H) 
Paracellular permeability expressed as permeability coefficient of bEND3 cells treated 
with VCR. Values are mean+/- SEM. Statistical analysis was performed by using 
Student’s t test *p<0.05 compared to saline treated cells. 
Figure 2. Increased monocyte adhesion to and infiltration into the spinal cord 24 
hours after one dose of VCR. (A-B) Representative images from a time series of 
spinal cords taken from saline (A) and VCR-treated (B) mice. Blood vessels are 
labelled with dextran fluorescein (green) and monocytes are tagged with CCR2-RFP 
(red). Scale bar = 100 μm. (C) Quantification of the number of CCR2-RFP + profiles 
observed outside of the vessel. One dose of VCR significantly increases RFP+ profiles 
found in spinal cord tissue (mean +/- SEM, n = 5 mice per group). * p < 0.05, Student’s 
paired t-test. (D) Quantification of the number of CCR2-RFP+ profiles observed at the 
endothelium. One dose of VCR significantly increases RFP+ profiles found in spinal 
cord tissue (mean +/- SEM, n = 5 mice per group). * p < 0.05, Student’s paired t-test. 
Figure 3. One cycle of VCR treatment significantly increases vascular 
permeability in brain and spinal cord. (A) Observation of paws prior to tissue 
harvesting showed no obvious difference in Evans Blue (EB) accumulation between 
saline-treated and VCR-treated mice. (B) Quantification of EB (expressed as ng/mg of 
tissue) in liver tissue from saline- and VCR-treated mice (mean+/- SEM, n = 7-8 mice 
per group). (C,D) Quantification of EB in brain (C) and spinal cord (D) from saline- 
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and VCR-treated mice (mean+/- SEM, n = 7-8 mice per group). ** p < 0.01, *** p < 
0.005, one-way ANOVA, post-hoc Tukey test. 
Figure 4. One cycle of VCR treatment disrupts expression of tight junction 
proteins in the spinal cord. (A and C) Representative blots of either Claudin-5 (A, 
24 kDa) or ZO-1 (B, 187 kDa) and -actin loading control (42 kDa) in lumbar spinal 
cord dorsal horn homogenates obtained from wild-type mice treated with one cycle of 
VCR or saline controls (days 0-4 inclusive). (B and D) Quantification of claudin-5 (B) 
and ZO-1 (D) band density normalised to loading control. VCR treatment significantly 
decreases the expression of both proteins in spinal cord homogenates. (n = 3 mice). 
* p < 0.05, ** p < 0.01, one-way ANOVA, post-hoc Tukey test. (E) Representative 
images of claudin 5 (green) and CCR2 (RFP, red) in lumbar spinal cord sections 
(dorsal horn) from saline-treated and VCR-treated mice. Nuclear stain DAPI in blue. 
(F) Representative images of ZO-1 (green) and CCR2 (RFP, red) in lumbar spinal cord 
sections (dorsal horn) from saline-treated and VCR-treated mice. Nuclear stain DAPI 
in blue Scale bars in panels in E and F = 10 μm. 
Figure 5. One cycle of VCR treatment results in monocytes/macrophages 
infiltration and CatS elevation in the spinal cord. (A) Representative images 
showing microglia/macrophage marker Iba1 (green) in saline-treated and VCR-treated 
lumbar spinal cord dorsal horn from CCR2-RFP heterozygous mice. CCR2 
immunoreactivity (RFP, red, merge yellow) is only found in Iba1+ cells in spinal cords 
from VCR-treated mice. (B) Representative image showing TMEM119 
immunoreactivity (green, resident microglia marker). No CCR2 (RFP, red) 
immunoreactivity is found in TMEM119+ cells. Nuclear marker DAPI in blue. (C) 
Representative image showing Ly6C immunoreactivity (green, monocyte/macrophage 
marker). CCR2 (RFP, red) immunoreactivity is found in Ly6C+ cells. Nuclear marker 
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DAPI in blue. (D) Representative blot and quantification of CatS (37 kDa) and -actin 
loading control (42 kDa) in lumbar spinal cord dorsal horn homogenates obtained from 
wild-type mice treated with one cycle of VCR (or saline controls). One cycle of VCR 
significantly increases CatS expression. (n = 3 mice). *p < 0.05, one-way ANOVA, 
Tukey test. (E,F) Representative image showing CatS immunoreactivity (green) in 
lumbar spinal cord dorsal horn from mice treated with one cycle of VCR. CCR2 (RFP, 
red) immunoreactivity is only found in CatS+ cells (yellow) with a phagocytic 
phenotype. Nuclear marker DAPI in blue. Scale bar in all panels = 10 μm. 
Figure 6. CatS inhibitors reduce VCR-induced mechanical hypersensitivity only 
when centrally-penetrant. (A) Mechanical thresholds are significantly higher in VCR- 
treated male and female mice (days 0-4 inclusive), which also received the centrally- 
penetrant MIV-247 (MIV) (200 µmol/kg p.o. twice a day, every day) alongside VCR 
than in VCR/vehicle-treated mice. Data expressed as 50% paw withdrawal thresholds 
(mean+/- SEM, n = 7 mice per group, 4 female and 3 male) measured 3 hours after 
administration. *** p < 0.001 compared to Saline/VEH group; ### p<0.001 compared 
to VCR/VEH group, Repeated Measures ANOVA, post hoc Tukey test. (B) Mechanical 
thresholds in mice treated with VCR (days 0-4 inclusive) are not altered 3 hours after 
administration of the peripherally-restricted RO5461111 (RO5) (200µmol/kg p.o. twice 
a day, every day) alongside VCR. Data expressed as 50% paw withdrawal thresholds 
(mean+/- SEM, n = 7 mice per group). *** p < 0.001 compared to Saline/VEH and 
Saline/RO5 groups Repeated Measures ANOVA, post hoc Tukey test. (C-D) 
Representative blot (C) and quantification (D) of li p10 fragment expression relative to 
li in snap frozen spleen from R05-treated and control mice (3 hours after 
administration) (n = 3 mice +/- SEM) ** p < 0.01, Student’s t-test. 
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Figure 7. Changes in vascular permeability following VCR treatment result in the 
infiltration of monocytes, which play a role in central mechanisms of pain. 1) 
Following treatment with vincristine (VCR), endothelial cells at the blood-spinal cord 
barrier upregulate adhesion molecules and are thus activated. 2a) VCR treatment also 
disrupts tight junction organization between endothelial cells and so monocytes, 
(which express CCR2 and are thus attracted by endothelial-expressed CCL2), are able 
to infiltrate into the spinal cord (2b). 3) Infiltrating monocytes provide a source of 
cathepsin S (CatS). 4) Cat S cleaves fractalkine (FKN) expressed by dorsal horn 
neurons. 5) Soluble FKN (sFKN) activates CX3CR1 receptors expressed by microglia, 
which in turn release proinflammatory, pronociceptive cytokines (6). 
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